Ascendis Pharma A (ASND) Retained Earnings (2012 - 2020)

Ascendis Pharma A (ASND) has 8 years of Retained Earnings data on file, last reported at -$22.7 million in Q4 2020.

• For the quarter ending Q4 2020, Retained Earnings fell 26.46% year-over-year to -$22.7 million; the trailing twelve-month figure through Dec 2020 stood at -$22.7 million (down 26.46% YoY), and the FY2020 full-year result was -$22.7 million, down 24.98% from the prior year.
• Retained Earnings declined to -$22.7 million in Q4 2020, from -$18.0 million in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of $208.3 million in Q3 2017 to a low of -$22.7 million in Q4 2020.
• A 4-year average of $94.7 million and a median of $100.1 million in 2016 frame the typical range for Retained Earnings.
• Across the five-year window, Retained Earnings tumbled 51.28% in 2016 and soared 211.87% in 2017, its largest moves.
• Tracing ASND's Retained Earnings over 4 years: stood at $172.0 million in 2016, then climbed by 21.16% to $208.3 million in 2017, then tumbled by 108.62% to -$18.0 million in 2019, then slipped by 26.46% to -$22.7 million in 2020.
• Business Quant data shows ASND's Retained Earnings at -$22.7 million in Q4 2020, -$18.0 million in Q4 2019, and $208.3 million in Q3 2017.